scinapse is loading now...

News Feature: Asia's big problem

Published on Apr 1, 2004in Nature Medicine 32.62
· DOI :10.1038/nm0404-325
Apoorva Mandavilli7
Estimated H-index: 7
,
David Cyranoski31
Estimated H-index: 31
Abstract
All the world loves to mock obese Americans, but weightier issues lurk in Asia, where diabetes and heart disease run rampant. The first hurdle may be a Western measure that is blind to the expanding fat in Asians' deceptively thin bodies.
  • References (0)
  • Citations (38)
Cite
References0
Newest
Cited By38
Newest
Published on May 1, 2019in Journal of Diabetes Investigation 3.15
Mayumi Yamamoto3
Estimated H-index: 3
(Gifu University),
Takahiro Watanabe8
Estimated H-index: 8
+ 3 AuthorsAkihiro Nishio4
Estimated H-index: 4
(Gifu University)
Source Cite
Published on Oct 1, 2017in Current Diabetes Reports 3.57
Madhur Agrawal4
Estimated H-index: 4
(Boston University),
Philip A. Kern54
Estimated H-index: 54
(University of Kentucky),
Barbara S. Nikolajczyk26
Estimated H-index: 26
(Boston University)
Purpose of Review Adipose tissue (AT) houses both innate and adaptive immune systems that are crucial for preserving AT function and metabolic homeostasis. In this review, we summarize recent information regarding progression of obesity-associated AT inflammation and insulin resistance. We additionally consider alterations in AT distribution and the immune system in males vs. females and among different racial populations.
10 Citations Source Cite
Published on Jun 1, 2017in Obesity science & practice
Rieko Nakano2
Estimated H-index: 2
(Iwate Medical University),
Noriko Takebe10
Estimated H-index: 10
(Iwate Medical University)
+ 8 AuthorsJo Satoh28
Estimated H-index: 28
SummaryIntroduction Co-existing decreased muscle mass and increased visceral fat, an age-associated change called sarcopenic obesity, results in fragility and cardiovascular disease. To assess the pathogenesis of sarcopenic obesity, we assessed the associations of clinical parameters with psoas muscle mass in elderly male subjects with obesity and type 2 diabetes. Methods The subjects were 55 patients, over 65 years of age and with a visceral fat area exceeding 100 cm2, with type 2 diabetes. The...
1 Citations Source Cite
Published on Mar 1, 2017in Journal of Diabetes Investigation 3.15
Makito Tanabe10
Estimated H-index: 10
(Fukuoka University),
Ryoko Motonaga3
Estimated H-index: 3
(Fukuoka University)
+ 2 AuthorsToshihiko Yanase43
Estimated H-index: 43
(Fukuoka University)
Aims/Introduction In treatment algorithms of type 2 diabetes mellitus in Western countries, biguanides are recommended as first-line agents. In Japan, various oral hypoglycemic agents (OHAs) are available, but prescription patterns are unclear. Materials and Methods Data of 7,108 and 2,655 type 2 diabetes mellitus patients in study 1 and study 2, respectively, were extracted from the Medical Data Vision database (2008–2013). Cardiovascular disease history was not considered in study 1, but was i...
11 Citations Source Cite
Published on Feb 3, 2017in PLOS ONE 2.77
Ichiro Tokubuchi6
Estimated H-index: 6
(Kurume University),
Yuji Tajiri10
Estimated H-index: 10
(Kurume University)
+ 6 AuthorsKentaro Yamada29
Estimated H-index: 29
(Kurume University)
Objective Metformin is known to have a beneficial effect on body weight and body composition, although the precise mechanism has not been elucidated yet. The aim of this study is to investigate the effects of metformin on energy metabolism and anthropometric factors in both human subjects and rats. Methods In human studies, metformin (1500mg/day) was administered to 23 healthy subjects and 18 patients with type 2 diabetes for 2 weeks. Metabolic parameters and energy metabolism were measured duri...
20 Citations Source Cite
Published on Sep 1, 2016in Journal of Diabetes Investigation 3.15
Wilfred Y. Fujimoto60
Estimated H-index: 60
(University of Washington)
The rising tide of diabetes in Asia has been preceded by high prevalence rates of diabetes among migrant Asian populations in the USA and elsewhere. A 1963 report from Hawaii showed that diabetes was much more prevalent in Japanese Americans than in Caucasians. The Japanese American Community Diabetes Study was begun in Seattle, Washington, to examine why this was the case, and explore the etiology and pathogenesis of type 2 diabetes among Japanese Americans who were Nisei (second generation) an...
3 Citations Source Cite
Published on Mar 1, 2015in Diabetology international
Atsushi Hiraoka19
Estimated H-index: 19
,
Yusuke Imai5
Estimated H-index: 5
+ 17 AuthorsHiromasa Nakahara8
Estimated H-index: 8
Aim The clinical features of fatty liver (FL) detected by ultrasonography (US) in nonobese and diabetes mellitus type 2 are not yet understood, and metabolic syndrome (MetS) has become an important health issue throughout the world. We investigated the clinical features of fatty liver (FL) in nonobese patients.
1 Citations Source Cite
Published on Feb 1, 2015in American Journal of Cardiology 3.17
Shigemasa Tani17
Estimated H-index: 17
(Nihon University),
Atsuhiko Takahashi9
Estimated H-index: 9
(Nihon University)
+ 1 AuthorsAtsushi Hirayama39
Estimated H-index: 39
(Nihon University)
Dipeptidyl peptidase-4 (DPP-4) inhibitors may affect the serum levels of plasminogen activator inhibitor-1 (PAI-1) associated with triglyceride (TG) metabolism, which is a prognostic factor for cardiovascular disease, in diabetic patients. We conducted an 8-week, prospective, randomized study in which we assigned type 2 diabetic patients who were inadequately controlled with antidiabetic therapy to the vildagliptin group (50 mg bid, n = 49) or the control group (n = 49). The primary efficacy par...
10 Citations Source Cite
Published on Jul 1, 2014in Therapeutics and Clinical Risk Management 2.00
Hiroyuki Konya9
Estimated H-index: 9
,
Yuzo Yano4
Estimated H-index: 4
+ 9 AuthorsTomoya Hamaguchi12
Estimated H-index: 12
Saxagliptin is a selective and potent dipeptidyl peptidase (DPP)-4 inhibitor, approved as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus (T2DM) in the USA on July 2009, and had been launched globally in over 86 countries by September 2013. In patients with T2DM, once-daily administration of saxagliptin before breakfast achieves sustained inhibition of plasma DPP-4 activity and reduction of postprandial hyperglycemia, including after dinner, associated wit...
7 Citations Source Cite